Trial to Reduce Cardiovascular Events with Aranesp Therapy.
Phase of Trial: Phase III
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Darbepoetin alfa (Primary)
- Indications Anaemia
- Focus Adverse reactions; Registrational
- Acronyms TREAT
- Sponsors Amgen
- 01 Oct 2015 Pooled analysis of 2 studies of total 4854 patients including patients from this TREAT trial and other RED-HF trial [see CTP 700244591] were published in the European Journal of Heart Failure.
- 05 Nov 2010 New trial record.